Representing many of the leading pharmaceutical companies in the industry, the ACS Green Chemistry Institute® (ACS GCI) Pharmaceutical Roundtable helps the pharmaceutical industry to enhance its sustainability performance in developing and manufacturing medicines that improve people’s lives.

OUR MISSION
The first of the ACS GCI Roundtables, the Pharmaceutical Roundtable launched in 2005. ACS GCI and global pharmaceutical corporations developed the Roundtable to encourage innovation and the integration of green chemistry and green engineering in the pharmaceutical industry. The activities of the Roundtable reflect the joint belief that the pursuit of green chemistry and green engineering is imperative for a sustainable business and world environment.

Through its work, the Roundtable has awarded more than $1.85 million to academic researchers worldwide. It has also leveraged $1.3 million of federal funding that was directed toward green chemistry research areas relevant to the pharmaceutical industry. The research has enabled an expanded toolbox of reactions for chemists to manufacture important medicines in a more environmentally benign fashion.

STRATEGIC PRIORITIES
- Inform and influence the research agenda to focus on green and sustainable chemistry
  - Fund research grants in key areas expanding academic-industry partnerships, publish manuscripts detailing the industry’s current needs, collaborate globally to harmonize green metrics
- Define and deliver tools to enable green chemistry innovation
  - Reagent selection guide, updated solvent selection guide, Process Mass Intensity/Life Cycle Assessment (PMI/LCA) calculator tool
- To promote education and training in pharmaceutical green chemistry
  - Share best practices, develop educational materials, and participate in the ACS GCI Education Roadmap
- Enable global collaboration among the sector companies
  - Expanding green chemistry collaboration with colleagues around the world; further outreach to generics and biologics

OUR VISION FOR 2025
By informing & influencing the research agenda:
- Life Cycle Assessment is used routinely to evaluate products and processes
- Suppliers use ‘green’ as a qualifier
- The pharmaceutical industry has fully implemented continuous manufacturing and integrated production.

By creating tools for innovation, we have:
- A database of highly efficient transformations
- A toolbox for greener route design available for use
- Standard quantitative key performance indicators (KPIs) and measures of greenness

By educating future leaders:
- Green chemistry is incorporated into every chemistry degree

To join the ACS GCI Pharmaceutical Roundtable or for more information, contact gcipr@acs.org or 202-872-6102.
PHARMACEUTICAL ROUNDTABLE MEMBERSHIP
The ACS GCI Pharmaceutical Roundtable welcomes the active participation of any corporation, or subsidiary, significantly engaged in the manufacture and marketing of finished dosage from ethical pharmaceutical or biological products under its own brand names for the cure, alleviation, mitigation, treatment, prevention or diagnosis of disease. In addition, members are welcomed who significantly engage in pharmaceutical, biopharmaceutical or biological research and development of new molecular entities; or new therapies, preventative, or in vivo diagnostics; or new systems of therapy, prevention, or diagnosis and who will continue to conduct such research and development.

- Annual fees range from $10,000 to $25,000 depending on membership type and company sales
- Each member company may designate employees to participate
- Three in-person meetings yearly (US and EU) – all accessible via web for global collaboration
- Team members meet virtually as needed to move projects forward

ROUNDTABLE MEMBER COMPANIES

To join the ACS GCI Pharmaceutical Roundtable or for more information, contact gcipr@acs.org, or 202-872-6102.

Updated June 8, 2017